Shuyu Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shuyu Wang has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Lingling Lei
Department of Human Reproductive Medicine, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, China
4 shared publicationsQiaoli Zhang
Department of Human Reproductive Medicine, Beijing Obstetrics and Gynecology Hospital Capital Medical University. Beijing Maternal and Child Health Care Hospital Beijing China
4 shared publicationsChanwei Jia
Department of Human Reproductive Medicine, Beijing Obstetrics and Gynecology Hospital Capital Medical University. Beijing Maternal and Child Health Care Hospital Beijing China
3 shared publicationsXiaokui Yang
Department of Human Reproductive Medicine, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, China
3 shared publicationsXiaomeng Bu
Department of Human Reproductive Medicine, Beijing Obstetrics and Gynecology Hospital Capital Medical University. Beijing Maternal and Child Health Care Hospital Beijing China
3 shared publicationsYanjun Liu
Department of Human Reproductive Medicine, Beijing Obstetrics and Gynecology Hospital Capital Medical University. Beijing Maternal and Child Health Care Hospital Beijing China
3 shared publications
Latest Publications
- Open Access
- 11 May 2023
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 23 (1) , 1-6
Successful pregnancy and delivery after ovulation induction therapy in a woman with congenital hypogonadotropic hypogonadism: a case report
Congenital hypogonadotropic hypogonadism (CHH) is a rare disorder resulting from a deficient secretion of the episodic gonadotropin-releasing hormone, leading to delayed or absent puberty and infertility. In female patients with CHH, the most commonly used treatment is gonadotropin (Gn) therapy. Due to the rarity of the disease in females, there are limited case reports available. This article offers a management approach for this unusual disease that can be helpful for clinicians. We report the case of a 29-year-old woman who successfully achieved pregnancy and delivered healthy twin girls after ovulation induction therapy. The patient was diagnosed with CHH at 18 years of age due to primary amenorrhea and the absence of secondary sexual characteristics. After experiencing infertility for three years, the patient sought medical assistance for conceiving. The patient was treated with gonadotropin therapy due to anovulation. In her first treatment cycle, the initial dose of HMG used for treatment was 75IU, which was increased to 150IU after six days. However, the cycle was canceled due to follicular dysplasia. In the second cycle, the treatment began with an initial dose of 150IU, and the follicles grew normally, but the estrogen level was low. Consequently, the treatment was interrupted. In a third ovulation stimulation cycle, HMG was adjusted to 150IU, and recombinant LH was added. After 12 days of ovulation, three mature follicles grew, the estrogen level was normal,and the treatment resulted in successful ovulation and subsequent pregnancy. At 35 weeks of gestation, the patient underwent a cesarean section and delivered two healthy female infants weighing 2,405 g and 2,755 g with an Apgar score of 10/10. Early diagnosis and timely and appropriate hormone replacement therapy are important for future pregnancy. Ovulation induction therapy is necessary to stimulate fertility. Gn therapy is a feasible and effective treatment for reproduction in CHH females, but the selection of Gn type and dosage must be personalized to maximize fertility outcomes. Effective treatment is available not only for inducing estrogenization and promoting fertility, but also for addressing concerns about psychological and emotional well-being.
- 11 May 2023
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 23 (1) , 1-6
Open AccessSuccessful pregnancy and delivery after ovulation induction therapy in a woman with congenital hypogonadotropic hypogonadism: a case report
Congenital hypogonadotropic hypogonadism (CHH) is a rare disorder resulting from a deficient secretion of the episodic gonadotropin-releasing hormone, leading to delayed or absent puberty and infertility. In female patients with CHH, the most commonly used treatment is gonadotropin (Gn) therapy. Due to the rarity of the disease in females, there are limited case reports available. This article offers a management approach for this unusual disease that can be helpful for clinicians. We report the case of a 29-year-old woman who successfully achieved pregnancy and delivered healthy twin girls after ovulation induction therapy. The patient was diagnosed with CHH at 18 years of age due to primary amenorrhea and the absence of secondary sexual characteristics. After experiencing infertility for three years, the patient sought medical assistance for conceiving. The patient was treated with gonadotropin therapy due to anovulation. In her first treatment cycle, the initial dose of HMG used for treatment was 75IU, which was increased to 150IU after six days. However, the cycle was canceled due to follicular dysplasia. In the second cycle, the treatment began with an initial dose of 150IU, and the follicles grew normally, but the estrogen level was low. Consequently, the treatment was interrupted. In a third ovulation stimulation cycle, HMG was adjusted to 150IU, and recombinant LH was added. After 12 days of ovulation, three mature follicles grew, the estrogen level was normal,and the treatment resulted in successful ovulation and subsequent pregnancy. At 35 weeks of gestation, the patient underwent a cesarean section and delivered two healthy female infants weighing 2,405 g and 2,755 g with an Apgar score of 10/10. Early diagnosis and timely and appropriate hormone replacement therapy are important for future pregnancy. Ovulation induction therapy is necessary to stimulate fertility. Gn therapy is a feasible and effective treatment for reproduction in CHH females, but the selection of Gn type and dosage must be personalized to maximize fertility outcomes. Effective treatment is available not only for inducing estrogenization and promoting fertility, but also for addressing concerns about psychological and emotional well-being.
- Open Access
- 21 February 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (5) , 1740
Pregnancy Outcomes of Freeze-All versus Fresh Embryo Transfer in Women with Adenomyosis: A Retrospective Study
Adenomyosis has been associated with adverse fertility and pregnancy outcomes, and its impact on the outcomes of in vitro fertilization (IVF) has received much attention. It is controversial whether the freeze-all strategy is better than fresh embryo transfer (ET) in women with adenomyosis. Women with adenomyosis were enrolled in this retrospective study from January 2018 to December 2021 and were divided into two groups: freeze-all (n = 98) and fresh ET (n = 91). Data analysis showed that freeze-all ET was associated with a lower rate of premature rupture of membranes (PROM) compared with fresh ET (1.0% vs. 6.6%, p = 0.042; adjusted OR 0.17 (0.01–2.50), p = 0.194). Freeze-all ET also had a lower risk of low birth weight compared with fresh ET (1.1% vs. 7.0%, p = 0.049; adjusted OR 0.54 (0.04–7.47), p = 0.642). There was a nonsignificant trend toward a lower miscarriage rate in freeze-all ET (8.9% vs. 11.6%; p = 0.549). The live birth rate was comparable in the two groups (19.1% vs. 27.1%; p = 0.212). The freeze-all ET strategy does not improve pregnancy outcomes for all patients with adenomyosis and may be more appropriate for certain patients. Further large-scale prospective studies are needed to confirm this result.
- 21 February 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (5) , 1740
Open AccessPregnancy Outcomes of Freeze-All versus Fresh Embryo Transfer in Women with Adenomyosis: A Retrospective Study
Adenomyosis has been associated with adverse fertility and pregnancy outcomes, and its impact on the outcomes of in vitro fertilization (IVF) has received much attention. It is controversial whether the freeze-all strategy is better than fresh embryo transfer (ET) in women with adenomyosis. Women with adenomyosis were enrolled in this retrospective study from January 2018 to December 2021 and were divided into two groups: freeze-all (n = 98) and fresh ET (n = 91). Data analysis showed that freeze-all ET was associated with a lower rate of premature rupture of membranes (PROM) compared with fresh ET (1.0% vs. 6.6%, p = 0.042; adjusted OR 0.17 (0.01–2.50), p = 0.194). Freeze-all ET also had a lower risk of low birth weight compared with fresh ET (1.1% vs. 7.0%, p = 0.049; adjusted OR 0.54 (0.04–7.47), p = 0.642). There was a nonsignificant trend toward a lower miscarriage rate in freeze-all ET (8.9% vs. 11.6%; p = 0.549). The live birth rate was comparable in the two groups (19.1% vs. 27.1%; p = 0.212). The freeze-all ET strategy does not improve pregnancy outcomes for all patients with adenomyosis and may be more appropriate for certain patients. Further large-scale prospective studies are needed to confirm this result.
- Open Access
- 1 January 2023
- Published by Tohoku University Medical Press in The Tohoku Journal of Experimental Medicine
- Vol. 259 (1) , 9-15
Diagnostic and Prognostic Value of Deregulated Long Non-Coding RNA Plasmacytoma Variant Translocation 1 in Patients with Gestational Hypertension
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- 1 January 2023
- Published by Tohoku University Medical Press in The Tohoku Journal of Experimental Medicine
- Vol. 259 (1) , 9-15
Open AccessDiagnostic and Prognostic Value of Deregulated Long Non-Coding RNA Plasmacytoma Variant Translocation 1 in Patients with Gestational Hypertension
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
- Open Access
- 5 June 2022
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 159 (3) , 944-950
Comparison of bromocriptine and hydroxyethyl starch in the prevention of ovarian hyperstimulation syndrome
Objective: To evaluate the effectiveness of bromocriptine for prevention of ovarian hyperstimulation syndrome (OHSS). Methods: The retrospective study included women at risk of OHSS who were receiving gonadotropin‐releasing hormone antagonist protocols, including 52 women given 2.5 mg bromocriptine by rectal insertion, 52 women given 500 ml intravenous hydroxyethyl starch (HES), and 40 women who received no intervention. Treatments were administered daily for 5 days beginning on the day of oocyte retrieval. Baseline information and data related to OHSS were compared. Results: No significant differences were found among groups in estradiol concentration on the day of trigger or in number of retrieved oocytes. Incidence of mild OHSS was not significantly different among groups, respectively 13.5%, 15.4%, and 17.5% ( P > 0.05). The incidence of moderate to severe OHSS was significantly lower in the bromocriptine and HES groups compared with the control group, respectively 7.7%, 5.8%, and 22.5% ( P < 0.05). D‐dimer levels were significantly lower in the bromocriptine and HES groups compared with the control group on Day 5 after oocyte retrieval ( P < 0.05). No differences in liver or renal function were found in the three groups. Conclusion: Bromocriptine was apparently as effective as intravenous HES in patients with high risk of OHSS.
- 5 June 2022
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 159 (3) , 944-950
Open AccessComparison of bromocriptine and hydroxyethyl starch in the prevention of ovarian hyperstimulation syndrome
Objective: To evaluate the effectiveness of bromocriptine for prevention of ovarian hyperstimulation syndrome (OHSS). Methods: The retrospective study included women at risk of OHSS who were receiving gonadotropin‐releasing hormone antagonist protocols, including 52 women given 2.5 mg bromocriptine by rectal insertion, 52 women given 500 ml intravenous hydroxyethyl starch (HES), and 40 women who received no intervention. Treatments were administered daily for 5 days beginning on the day of oocyte retrieval. Baseline information and data related to OHSS were compared. Results: No significant differences were found among groups in estradiol concentration on the day of trigger or in number of retrieved oocytes. Incidence of mild OHSS was not significantly different among groups, respectively 13.5%, 15.4%, and 17.5% ( P > 0.05). The incidence of moderate to severe OHSS was significantly lower in the bromocriptine and HES groups compared with the control group, respectively 7.7%, 5.8%, and 22.5% ( P < 0.05). D‐dimer levels were significantly lower in the bromocriptine and HES groups compared with the control group on Day 5 after oocyte retrieval ( P < 0.05). No differences in liver or renal function were found in the three groups. Conclusion: Bromocriptine was apparently as effective as intravenous HES in patients with high risk of OHSS.
- Open Access
- 19 May 2022
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 13, 847249
Brown Adipose Tissue and Novel Management Strategies for Polycystic Ovary Syndrome Therapy
Brown adipose tissue (BAT), a unique tissue, plays a key role in metabolism and energy expenditure through adaptive nonshivering thermogenesis. It has recently become a therapeutic target in the treatment of obesity and metabolic diseases. The thermogenic effect of BAT occurs through uncoupling protein-1 by uncoupling adenosine triphosphate (ATP) synthesis from energy substrate oxidation. The review discusses the recent developments and progress associated with the biology, function, and activation of BAT, with a focus on its therapeutic potential for the treatment of polycystic ovary syndrome (PCOS). The endocrine activity of brown adipocytes affects the energy balance and homeostasis of glucose and lipids, thereby affecting the association of BAT activity and the metabolic profile. PCOS is a complex reproductive and metabolic disorder of reproductive-age women. Functional abnormalities of adipose tissue (AT) have been reported in patients with PCOS. Numerous studies have shown that BAT could regulate the features of PCOS and that increases in BAT mass or activity were effective in the treatment of PCOS through approaches including cold stimulation, BAT transplantation and compound activation in various animal models. Therefore, BAT may be used as a novel management strategy for the patients with PCOS to improve women’s health clinically. It is highly important to identify key brown adipokines for the discovery and development of novel candidates to establish an efficacious therapeutic strategy for patients with PCOS in the future.
- 19 May 2022
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 13, 847249
Open AccessBrown Adipose Tissue and Novel Management Strategies for Polycystic Ovary Syndrome Therapy
Brown adipose tissue (BAT), a unique tissue, plays a key role in metabolism and energy expenditure through adaptive nonshivering thermogenesis. It has recently become a therapeutic target in the treatment of obesity and metabolic diseases. The thermogenic effect of BAT occurs through uncoupling protein-1 by uncoupling adenosine triphosphate (ATP) synthesis from energy substrate oxidation. The review discusses the recent developments and progress associated with the biology, function, and activation of BAT, with a focus on its therapeutic potential for the treatment of polycystic ovary syndrome (PCOS). The endocrine activity of brown adipocytes affects the energy balance and homeostasis of glucose and lipids, thereby affecting the association of BAT activity and the metabolic profile. PCOS is a complex reproductive and metabolic disorder of reproductive-age women. Functional abnormalities of adipose tissue (AT) have been reported in patients with PCOS. Numerous studies have shown that BAT could regulate the features of PCOS and that increases in BAT mass or activity were effective in the treatment of PCOS through approaches including cold stimulation, BAT transplantation and compound activation in various animal models. Therefore, BAT may be used as a novel management strategy for the patients with PCOS to improve women’s health clinically. It is highly important to identify key brown adipokines for the discovery and development of novel candidates to establish an efficacious therapeutic strategy for patients with PCOS in the future.
- 10 November 2021
- Published by Springer Nature in Chinese Journal of Integrative Medicine
- Vol. 28 (5) , 434-439
Effects of Transcutaneous Electrical Acupoint Stimulation on Ovarian Responses and Pregnancy Outcomes in Patients Undergoing IVF-ET: A Randomized Controlled Trial
Objective To evaluate the influence of different transcutaneous electrical acupoint stimulation (TEAS) modes on ovarian responses and pregnancy outcomes in patients with infertility undergoing in vitro fertilization and embryo transfer (IVF-ET). Methods Two hundred infertility patients undergoing IVF-ET were divided randomly into experimental groups (TEAS groups: E-I, E-II, E-III, and E-IV, 40 cases each group) and a control group (mock TEAS group, 40 patients) using the random number method. The patients in the experimental groups received TEAS treatment of 20, 30, 40 and 50 mA for the E-I, E-II, E-III and E-IV groups, respectively. The control group received a treatment of 5 mA. TEAS was applied at acupoints of Guanyuan (RN 4), Zhongji (RN 3), Sanyinjiao (SP 6), Zigong (EX-CA 1), and Taixi (KI 13), once a day for 30 min each time for a treatment period of 10–13 d. Treatment effect was assessed using the following indicators: endometrial thickness on the 6th day of gonadotropin treatment (GN6 day), endometrial thickness on the day on chorionic gonadotropin administration (HCG day), number of ovarian follicles on HCG day, number of ova captured, amount of estrogen required for each harvested ova, number of mature ova divided by the total number of ova, percentage of high-quality embryos, and clinical pregnancy. Results Endometrial thickness in the experimental groups on the HCG day was significantly better than that of the control group after TEAS stimulation (P=0.01). TEAS exhibited a greater impact on the number of ova captured (P=0.003). However, the effect of TEAS stimulation on the high-quality embryo rate and clinical pregnancy in patients was not statistically significant (P>0.05). Conclusions TEAS is an effective method in improving the ovarian state. When the stimulus intensity was at 40 mA and above, it could be helpful to improve the patient’s endometrial condition and endometrial receptivity and to retrieve more oocytes. (Trial registration No. ChiCTR-TRC-11001780)
- 10 November 2021
- Published by Springer Nature in Chinese Journal of Integrative Medicine
- Vol. 28 (5) , 434-439
Effects of Transcutaneous Electrical Acupoint Stimulation on Ovarian Responses and Pregnancy Outcomes in Patients Undergoing IVF-ET: A Randomized Controlled Trial
Objective To evaluate the influence of different transcutaneous electrical acupoint stimulation (TEAS) modes on ovarian responses and pregnancy outcomes in patients with infertility undergoing in vitro fertilization and embryo transfer (IVF-ET). Methods Two hundred infertility patients undergoing IVF-ET were divided randomly into experimental groups (TEAS groups: E-I, E-II, E-III, and E-IV, 40 cases each group) and a control group (mock TEAS group, 40 patients) using the random number method. The patients in the experimental groups received TEAS treatment of 20, 30, 40 and 50 mA for the E-I, E-II, E-III and E-IV groups, respectively. The control group received a treatment of 5 mA. TEAS was applied at acupoints of Guanyuan (RN 4), Zhongji (RN 3), Sanyinjiao (SP 6), Zigong (EX-CA 1), and Taixi (KI 13), once a day for 30 min each time for a treatment period of 10–13 d. Treatment effect was assessed using the following indicators: endometrial thickness on the 6th day of gonadotropin treatment (GN6 day), endometrial thickness on the day on chorionic gonadotropin administration (HCG day), number of ovarian follicles on HCG day, number of ova captured, amount of estrogen required for each harvested ova, number of mature ova divided by the total number of ova, percentage of high-quality embryos, and clinical pregnancy. Results Endometrial thickness in the experimental groups on the HCG day was significantly better than that of the control group after TEAS stimulation (P=0.01). TEAS exhibited a greater impact on the number of ova captured (P=0.003). However, the effect of TEAS stimulation on the high-quality embryo rate and clinical pregnancy in patients was not statistically significant (P>0.05). Conclusions TEAS is an effective method in improving the ovarian state. When the stimulus intensity was at 40 mA and above, it could be helpful to improve the patient’s endometrial condition and endometrial receptivity and to retrieve more oocytes. (Trial registration No. ChiCTR-TRC-11001780)
- 1 November 2021
- Published by Elsevier in Clinical Immunology
- Vol. 232, 108858
Progesterone-induced blocking factor-mediated Th1/Th2 balance correlates with fetal arrest in women who underwent in vitro fertilization and embryo transfer
- 1 November 2021
- Published by Elsevier in Clinical Immunology
- Vol. 232, 108858
Progesterone-induced blocking factor-mediated Th1/Th2 balance correlates with fetal arrest in women who underwent in vitro fertilization and embryo transfer
- 28 July 2021
- Published by Taylor & Francis in Growth Factors
- Vol. 39 (1-6) , 28-36
Vasomotor tone-associated factors and pregnancy outcomes of women who undergo in vitro fertilization
Vasomotor tone-associated factors play important roles in normal pregnancy, but their roles in the pregnancy outcome of women who undergo in vitro fertilization and embryo transfer (IVF-ET) remain unclear. A total of 82 infertile women who underwent successful IVF-ET were enrolled, including 18 pregnancy losses, 11 complications, and 53 normal deliveries. The serum NO and iNOS levels were significantly higher in the pregnancy loss group and significantly lower in the complication group than in the normal delivery group (p < 0.05). Significantly increased ET-1 and decreased PGI2 were found in both the pregnancy loss and complication groups compared with those in the normal delivery group (p < 0.05). NO, iNOS, and ET-1 are risk factors and PGI2 is a protective factor for pregnancy loss. ET-1 + PGI2 (AUC, 0.897; sensitivity, 90.6%; specificity, 83.3%) showed a relatively good predictive value for pregnancy loss following IVF-ET.
- 28 July 2021
- Published by Taylor & Francis in Growth Factors
- Vol. 39 (1-6) , 28-36
Vasomotor tone-associated factors and pregnancy outcomes of women who undergo in vitro fertilization
Vasomotor tone-associated factors play important roles in normal pregnancy, but their roles in the pregnancy outcome of women who undergo in vitro fertilization and embryo transfer (IVF-ET) remain unclear. A total of 82 infertile women who underwent successful IVF-ET were enrolled, including 18 pregnancy losses, 11 complications, and 53 normal deliveries. The serum NO and iNOS levels were significantly higher in the pregnancy loss group and significantly lower in the complication group than in the normal delivery group (p < 0.05). Significantly increased ET-1 and decreased PGI2 were found in both the pregnancy loss and complication groups compared with those in the normal delivery group (p < 0.05). NO, iNOS, and ET-1 are risk factors and PGI2 is a protective factor for pregnancy loss. ET-1 + PGI2 (AUC, 0.897; sensitivity, 90.6%; specificity, 83.3%) showed a relatively good predictive value for pregnancy loss following IVF-ET.
- Open Access
- 12 April 2021
- Published by Springer Nature in Research Square
Comparison of Bromocriptine and Hydroxyethyl Starch for Reducing Ohss in in Vitro Fertilization Patients: A Retrospective Study
Background: The ovarian hyperstimulation syndrome (OHSS) is a potentially life-threatening complication associated with controlled ovarian hyperstimulation (COS) during assisted reproductive technology (ART) treatment, and effective preventive measures are urgently needed. The dopamine agonist can mitigate OHSS incidence through a decreased vascular permeability via reduced vascular endothelial growth factor (VEGF) production. This study evaluated the clinical effectiveness of bromocriptine, an alternative DA, for prevention of OHSS in high risk women.Methods: The retrospective study population consisted of women undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) cycles with GnRH antagonist protocols, at risk of OHSS. The study group included 52 women given 2.5 mg bromocriptine daily by rectal insertion for 5 days beginning on the day of oocyte retrieval; the control group included 52 women given 500 ml intravenous (I.V.) hydroxyethyl starch (HES) daily for 5 days also beginning on the day of oocyte retrieval. The outcomes of ovarian stimulation, incidence and severity of OHSS, blood-related indicators, biochemical indicators (liver and renal function), and coagulation and fibrinolytic activities were compared.Results: The groups were not significantly different in age, estradiol concentration on the day of human chorionic gonadotropin injection, or number of retrieved oocytes. The occurrence of mild (13.46% vs 15.48%) and moderate (7.69% vs 5.77%) OHSS were not significantly different between bromocriptine and HES groups (P>0.05). No cases of severe or late OHSS were recorded in either group. Only hemocratin levels were significantly higher and activated partial thromboplastin time was significantly lower in the bromocriptine group (PConclusions: Prophylactic rectal administration of bromocriptine was as effective as I.V. HES for prevention of OHSS.
- 12 April 2021
- Published by Springer Nature in Research Square
Open AccessComparison of Bromocriptine and Hydroxyethyl Starch for Reducing Ohss in in Vitro Fertilization Patients: A Retrospective Study
Background: The ovarian hyperstimulation syndrome (OHSS) is a potentially life-threatening complication associated with controlled ovarian hyperstimulation (COS) during assisted reproductive technology (ART) treatment, and effective preventive measures are urgently needed. The dopamine agonist can mitigate OHSS incidence through a decreased vascular permeability via reduced vascular endothelial growth factor (VEGF) production. This study evaluated the clinical effectiveness of bromocriptine, an alternative DA, for prevention of OHSS in high risk women.Methods: The retrospective study population consisted of women undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) cycles with GnRH antagonist protocols, at risk of OHSS. The study group included 52 women given 2.5 mg bromocriptine daily by rectal insertion for 5 days beginning on the day of oocyte retrieval; the control group included 52 women given 500 ml intravenous (I.V.) hydroxyethyl starch (HES) daily for 5 days also beginning on the day of oocyte retrieval. The outcomes of ovarian stimulation, incidence and severity of OHSS, blood-related indicators, biochemical indicators (liver and renal function), and coagulation and fibrinolytic activities were compared.Results: The groups were not significantly different in age, estradiol concentration on the day of human chorionic gonadotropin injection, or number of retrieved oocytes. The occurrence of mild (13.46% vs 15.48%) and moderate (7.69% vs 5.77%) OHSS were not significantly different between bromocriptine and HES groups (P>0.05). No cases of severe or late OHSS were recorded in either group. Only hemocratin levels were significantly higher and activated partial thromboplastin time was significantly lower in the bromocriptine group (PConclusions: Prophylactic rectal administration of bromocriptine was as effective as I.V. HES for prevention of OHSS.
- Open Access
- 1 April 2021
- Published by AME Publishing Company in Annals of Palliative Medicine
- Vol. 10 (4) , 4391-4397
The effects of multiple controlled ovarian hyperstimulation over a 2-year period on ovarian reserve and reactivity: a retrospective clinical study
Background: To evaluate the effects of controlled ovarian hyperstimulation (COH) on ovarian reserve function during in vitro fertilization and embryo transfer (IVF-ET). Methods: From August 2018 to August 2020, the medical records of patients who received IVF-ET in the Department of Reproductive Medicine, Beijing Gynaecology and Obstetrics Hospital, Capital Medical University were analyzed retrospectively. Among them, 372 patients received 2 cycles of COH, 54 patients received 3 cycles, and 13 patients received 4 cycles. The levels of follicle-stimulating hormone (FSH), the number of antral follicles, levels of anti-Müllerian hormone (AMH), the total amount of gonadotropin (GN), the time of ovulation induction, the number of eggs obtained, the number of available embryos, and the number of high-quality embryos cycles were compared in different treatment. Results: The age of female patients did not significantly affect the levels of AMH or FSH during menstruation, nor the number of antral follicles before ovulation induction (P>0.05). However, with an increase in age, an increase in the number of controlled COH cycles was observed. In patients who underwent 2 COH cycles, the number of high-quality embryos in the second cycle increased significantly compared to the first cycle (P0.05). In patients with 3 treatment cycles, the GN dose used in the third cycle was significantly lower than that used in the first cycle (P0.05). In patients with 4 treatment cycles, significant differences were observed in the ovulation induction time between the first and the fourth controlled COH cycle (P0.05). Conclusions: Ovarian reserve function was not significantly affected in patients with up to 4 ovarian stimulation cycles.
- 1 April 2021
- Published by AME Publishing Company in Annals of Palliative Medicine
- Vol. 10 (4) , 4391-4397
Open AccessThe effects of multiple controlled ovarian hyperstimulation over a 2-year period on ovarian reserve and reactivity: a retrospective clinical study
Background: To evaluate the effects of controlled ovarian hyperstimulation (COH) on ovarian reserve function during in vitro fertilization and embryo transfer (IVF-ET). Methods: From August 2018 to August 2020, the medical records of patients who received IVF-ET in the Department of Reproductive Medicine, Beijing Gynaecology and Obstetrics Hospital, Capital Medical University were analyzed retrospectively. Among them, 372 patients received 2 cycles of COH, 54 patients received 3 cycles, and 13 patients received 4 cycles. The levels of follicle-stimulating hormone (FSH), the number of antral follicles, levels of anti-Müllerian hormone (AMH), the total amount of gonadotropin (GN), the time of ovulation induction, the number of eggs obtained, the number of available embryos, and the number of high-quality embryos cycles were compared in different treatment. Results: The age of female patients did not significantly affect the levels of AMH or FSH during menstruation, nor the number of antral follicles before ovulation induction (P>0.05). However, with an increase in age, an increase in the number of controlled COH cycles was observed. In patients who underwent 2 COH cycles, the number of high-quality embryos in the second cycle increased significantly compared to the first cycle (P0.05). In patients with 3 treatment cycles, the GN dose used in the third cycle was significantly lower than that used in the first cycle (P0.05). In patients with 4 treatment cycles, significant differences were observed in the ovulation induction time between the first and the fourth controlled COH cycle (P0.05). Conclusions: Ovarian reserve function was not significantly affected in patients with up to 4 ovarian stimulation cycles.